PARP1 and metastatic melanoma: In prior combination trials of PARP inhibitors with TMZ, hematologic AEs were also common for veliparib in small cell lung cancer or metastatic melanoma,19, 21 olaparib in recurrent glioblastoma,14 and talazoparib in advanced malignancies.16